PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Subcommittee on Health and Environment.
Congressional Research Service
Version 00 · Introduced in House · Jun 21, 2000
Public Investment Recovery Act of 2000 - Requires each transaction entered into by a Federal agency under which Federal support is provided for research and development which leads or may lead to the production and sale of a pharmaceutical, biologic, or genetic product to include provisions requiring that payments to recoup a portion of the agency's investment be paid annually to the Federal agency for deposit into a Public Investment Recovery Trust Fund established by this Act.Establishes a Public Investment Recovery Board to: (1) determine the total amount of profits for such a product; and (2) make calculations as required by this Act of the proportion of Federal support for research and development which lead to the production and sale of such a product. Prescribes a formula for determining the percentage of profits required to be paid.Provides for the expiration of payments on the expiration of the initial patent issued for such product.Allows: (1) not more than two percent of amounts in the Trust Fund to be used by the Food and Drug Administration or the National Institutes of Health (NIH) to support research and reports on the comparative efficiency and effectiveness of such products; (2) not more than 20 percent of amounts in the Trust Fund in the first five fiscal years after the enactment of this Act, and three percent in subsequent fiscal years, to be used to help pay the administrative expenses of carrying out this Act; and (3) not more than 20 percent of amounts in the Trust Fund to be used by NIH to support pharmaceutical, biologic, or genetic research and development, unless no Medicare prescription drug benefit has been enacted, in which case the remainder of the funds in such Fund may be used for a purpose authorized by this Act. Requires the remainder of such funds, if such a drug benefit has been enacted, to be used for the financing of such a benefit.
People & committees
Rep. Capuano, Michael E. [D-MA-8] · D–MA
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health and Environment.
Referred to the Subcommittee on Basic Research.
Sponsor introductory remarks on measure. (CR E1090)
Referred to the Committee on Commerce, and in addition to the Committees on Science, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Commerce, and in addition to the Committees on Science, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Commerce, and in addition to the Committees on Science, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Commerce, and in addition to the Committees on Science, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Jun 3, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.4705 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.4705 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.4705 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.4705 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.